Bacci G, Picci P, Ferrari S, Sangiorgi L, Zanone A, Brach del Prever A
Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy.
Eur J Cancer. 1994;30A(5):620-6. doi: 10.1016/0959-8049(94)90532-0.
28 patients with telangiectatic osteogenic sarcoma of the extremities were treated between March 1983 and March 1990 with neoadjuvant chemotherapy according to two different protocols activated successively. With the first protocol, patients preoperatively received high dose methotrexate (HDMTX)-cisplatinum (CDP) and postoperatively, depending on the histological response, either HDMTX-CDP-doxorubicin (ADM) or ADM-"BCD". With the second protocol patients were preoperatively treated with HDMTX-CDP-ADM and postoperatively either with the same drugs or with the same drugs plus ifosfamide and VP-16. Preoperatively, CDP was delivered intraarterially. A good histological response (tumour necrosis > 90%) was observed in 25 patients (89%) and at a mean follow-up of 5 years (2-9 years) 23 patients (82%) remained continuously disease-free and 5 developed lung metastases. These results are better than those obtained in 272 contemporary cases of conventional osteosarcoma of the extremities treated with the same protocols (62% good histological responses and 61% continuously disease-free survival).
1983年3月至1990年3月期间，28例肢体毛细血管扩张性骨肉瘤患者先后按照两种不同方案接受了新辅助化疗。在第一个方案中，患者术前接受大剂量甲氨蝶呤（HDMTX）-顺铂（CDP）治疗，术后根据组织学反应，要么接受HDMTX-CDP-阿霉素（ADM）治疗，要么接受ADM-“BCD”治疗。在第二个方案中，患者术前接受HDMTX-CDP-ADM治疗，术后要么接受相同药物治疗，要么接受相同药物加异环磷酰胺和VP-16治疗。术前，CDP通过动脉内给药。25例患者（89%）观察到良好的组织学反应（肿瘤坏死>90%），平均随访5年（2 - 9年），23例患者（82%）持续无病生存，5例发生肺转移。这些结果优于同期272例采用相同方案治疗的传统肢体骨肉瘤患者（62%良好组织学反应和61%持续无病生存率）。
